On 25 July 2019, orphan designation EU/3/19/1285 was granted by the European Commission to Incyte Biosciences Distribution B.V., the Netherlands, for parsaclisib for the treatment of marginal zone lymphoma.
|Disease / condition||
Treatment of marginal zone lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: